Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Steve Paul
AddedMar 31, 2024
UpdatedMay 31, 2026
Steve Paul

Steve Paul

Board Member, Voyager Therapeutics

CrunchbaseLinkedIn

Steve Paul's Career

Voyager Therapeutics
Voyager Therapeutics

Cambridge, MA, US

Board Member· Board
Sage Therapeutics
Sage Therapeutics

Cambridge, MA, US

Co-Founder
Tal Medical
Tal Medical

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Steve Paul's Career

Voyager Therapeutics
Voyager Therapeutics
Public$374M1252014Cambridge, MA, US
Board Member· Board

Leadership at Voyager Therapeutics

Krystof BankiewiczKrystof BankiewiczCo-Founder
Alfred SandrockAlfred SandrockBoard Member
Phillip D. ZamorePhillip D. ZamoreBoard Member
Michael J HigginsMichael J HigginsBoard Member
Nancy VitaleNancy VitaleBoard Member
Guangping GaoGuangping GaoBoard Member

Similar to Voyager Therapeutics

Poseida TherapeuticsPoseida TherapeuticsSan Diego, CA, USGene Therapiesest. 2014Poseida TherapeuticsSan Diego, CA, US · est. 2014

San Diego-based Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company innovating cell and gene therapeutics.

Public · $460.5M314
Kriya TherapeuticsKriya TherapeuticsPalo Alto, CA, USGene Therapiesest. 2019Kriya TherapeuticsPalo Alto, CA, US · est. 2019

Kriya Therapeutics: Pioneering gene therapies for global health challenges in ophthalmology, neurology, and metabolism.

Series C · $600.5M194
NeurogeneNeurogeneNew York, NY, USGenetic Medicinesest. 2018NeurogeneNew York, NY, US · est. 2018

Neurogene Inc., a New York-based pharmaceutical company, specializes in developing genetic medicines for rare neurological diseases.

Public · $183.5M92
Intellia TherapeuticsIntellia TherapeuticsCambridge, MA, USGene Editing, Therapiesest. 2014Intellia TherapeuticsCambridge, MA, US · est. 2014

Cambridge-based Intellia Therapeutics pioneers gene editing therapies for genetic diseases.

Public · $1.2B598
Sage Therapeutics
Sage Therapeutics
Public$2.7B6892010Cambridge, MA, US
Co-Founder

Leadership at Sage Therapeutics

Douglas CoveyDouglas CoveyCo-Founder
Jim FratesJim FratesBoard Member
Kevin StarrKevin StarrBoard Member
Barry GreeneBarry GreeneBoard Member
Tal Medical
Tal Medical
Series A$14.7M112011Boston, MA, US
Board Member· Board

Leadership at Tal Medical

Jan SkvarkaJan SkvarkaCEO
Daphne ZoharDaphne ZoharBoard Member
Andrew MillerAndrew MillerFounder
Dr Raju S KucherlapatiDr Raju S KucherlapatiBoard Member

Similar to Tal Medical

Niche BiomedicalNiche BiomedicalLos Angeles, CA, USMedical Devicesest. 2016Niche BiomedicalLos Angeles, CA, US · est. 2016

Niche Biomedical: Innovating neuromodulation devices for enhanced human health.

Pre-Seed · $1.4M15
RBI MedicalRBI MedicalWorcester, MA, USMedical Devicesest. 2019RBI MedicalWorcester, MA, US · est. 2019

RBI Medical: Revolutionizing pelvic health with safer, effective neuromodulation therapies.

Pre-Seed · $1.2M7
AvivomedAvivomedMinneapolis, MN, USNeuromodulation Therapyest. 2021AvivomedMinneapolis, MN, US · est. 2021

Avivomed: Innovating neuromodulation tech for chronic disease treatment.

Series A · $32M13
Cervel NeurotechCervel NeurotechRedwood City, CA, USMedical Devicesest. 2008Cervel NeurotechRedwood City, CA, US · est. 2008

Cervel Neurotech develops non-invasive neuro-modulation devices for treating psychiatric and neurological disorders.

Pre-Seed · $42.5M30

Steve Paul's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Steve Paul

Michael PelliniMichael PelliniBoard Member · Foundation MedicinePatrick GriffinPatrick GriffinBoard Member · Myosin TherapeuticsGary StevensonGary StevensonBoard Member · ZeroTo510Thomas InselThomas InselBoard Member · Vanna HealthScott StuartScott StuartBoard Member · Memorial Sloan Kettering Cancer CenterMichael GreeleyMichael GreeleyCo-Founder · Flare Capital Partners